Neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer

Future Oncology

Volumn 10, Issue 14, 2014, Pages 2243-2257

  Sclafani, Francesco ^a   Cunningham, David ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

chemoradiotherapy; MRI; neoadjuvant chemotherapy; radiotherapy; rectal cancer; total mesorectal excision

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB;

ADVANCED CANCER; ALGORITHM; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL PRACTICE; DISEASE FREE SURVIVAL; HUMAN; MULTIMODALITY CANCER THERAPY; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; RECURRENCE RISK; REVIEW; RISK REDUCTION; SHORT COURSE THERAPY; ADJUVANT THERAPY; ADVERSE EFFECTS; CANCER STAGING; CLINICAL TRIAL (TOPIC); PATHOLOGY; PROCEDURES; RECTAL NEOPLASMS; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84916640093     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.127     Document Type: Review

References (94)

1. Cancer Research UK. www.cancerresearchuk.org
2. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br. J. Surg. 93(10), 1215-1223 (2006).
3. Sebag-Montefore D, Stephens RJ, Steele R et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): A multicentre, randomised trial. Lancet 373(9666), 811-820 (2009).
4. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N. Engl. J. Med. 351(17), 1731-1740 (2004).
5. Sauer R, Liersch T, Merkel S et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized Phase III trial after a median follow-up of 11 years. J. Clin. Oncol. 30(16), 1926-1933 (2012).
6. Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N. Engl. J. Med. 345(9), 638-646 (2001).
7. Van Gijn W, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 12(6), 575-582 (2011).
8. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N. Engl. J. Med. 336(14), 980-987 (1997).
9. Folkesson J, Birgisson H, Pahlman L, Cedermark B, Glimelius B, Gunnarsson U. Swedish Rectal Cancer Trial: long lasting benefts from radiotherapy on survival and local recurrence rate. J. Clin. Oncol. 23(24), 5644-5650 (2005).
10. Cammá C, Giunta M, Fiorica F, Pagliaro L, Craxí A, Cottone M. Preoperative rdiotherapy for resectable rectal cancer: a meta-analysis. JAMA 284(8), 1008-1015 (2000).
11. Aschele C, Cionini L, Lonardi S et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized Phase III trial. J. Clin. Oncol. 29(20), 2773-2780 (2011).
12. Allegra CJ, Yothers GA, O'Connell MJ et al Neoadjuvant therapy for rectal cancer: mature results from NSABP protocol R-04. J. Clin. Oncol. 32, (Suppl. 3), Abstract 390 (2014).
13. Rödel C, Liersch T, Becker H et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fuorouracil and oxaliplatin versus fuorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised Phase 3 trial. Lancet Oncol. 13(7), 679-687 (2012).
14. Gérard J-P, Azria D, Gourgou-Bourgade S et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J. Clin. Oncol. 30(36), 4558-4565 (2012).
15. Dewdney A, Cunningham D, Tabernero J et al. Multicenter randomized Phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J. Clin. Oncol. 30(14), 1620-1627 (2012).
16. Bruheim K, Guren MG, Skovlund E et al. Late side effects and quality of life after radiotherapy for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 76(4), 1005-1011 (2010).
17. Brændengen M, Tveit KM, Bruheim K, Cvancarova M, Berglund A, Glimelius B. Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study. Int. J. Radiat. Oncol. Biol. Phys. 81(4), 1017-1024 (2011).
18. Marijnen CA, van de Velde CJ, Putter H et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J. Clin. Oncol. 23(9), 1847-1858 (2005).
19. Peeters KC, van de Velde CJ, Leer J W et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients-a Dutch Colorectal Cancer Group Study. J. Clin. Oncol. 23(25), 6199-6206 (2005).
20. Birgisson H, Påhlman L, Gunnarsson U, Bengt Glimelius. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J. Clin. Oncol. 23(25), 6126-6131 (2005).
21. Birgisson H, Påhlman L, Gunnarsson U, Glimelius B. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J. Clin. Oncol. 23(24), 8697-8705 (2005).
22. Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N. Engl. J. Med. 312(23), 1465-1472 (1985).
23. Local recurrence rate in a randomised multicentre trial of preoperative radiotherapy compared with operation alone in resectable rectal carcinoma. Swedish Rectal Cancer Trial. Eur. J. Surg. 162(5), 397-402 (1996).
24. Thaysen HV, Jess P, Laurberg S. Health-related quality of life after surgery for primary advanced rectal cancer and recurrent rectal cancer: a review. Colorectal Dis. 14(7), 797-803 (2012).
25. Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes. The Beyond TME Collaborative. Br. J. Surg. 100(8), 1009-1014 (2013).
26. Harnsberger JR, Vernava VM III, Longo WE. Radical abdominopelvic lymphadenectomy: historic perspective and current role in the surgical management of rectal cancer. Dis. Colon Rectum 37(1), 73-87 (1994).
27. Phillips RK, Hittinger R, Blesovsky L, Fry US, Fielding LP. Local recurrence following 'curative' surgery for large bowel cancer. I. The overall picture. Br. J. Surg. 71(1), 12-16 (1984).
28. Kapiteijn E, Marijnen C, Colenbrander AC et al. Local recurrence in patients with rectal cancer, diagnosed between 1988 and 1992: a population-based study in the west Netherlands. Eur. J. Surg. Oncol. 24(6), 528-535 (1998).
29. Stockholm Colorectal Cancer Study Group. Randomized study on preoperative radiotherapy in rectal carcinoma. Ann. Surg. Oncol. 3(5), 423-430 (1996).
30. Dahl O, Horn A, Morild I et al. Low-dose preoperative radiation postpones recurrences in operable rectal cancer. Results of a randomized multicenter trial in western Norway. Cancer. 66(11), 2286-2294 (1990).
31. Goldberg PA, Nicholls RJ, Porter NH, Love S, Grimsey JE. Long-term results of a randomised trial of short-course low-dose adjuvant pre-operative radiotherapy for rectal cancer: reduction in local treatment failure. Eur. J. Cancer 30A(11), 1602-1606 (1994).
32. Cedermark B, Johansson H, Rutqvist LE, Wilking N. The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group. Cancer 75(9), 2269-2275 (1995).
33. Medical Research Council Rectal Cancer Working Party. Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Lancet 348 (9042), 1605-1610 (1996).
34. Medical Research Council Rectal Cancer Working Party. Randomised trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of the rectum. Lancet 348 (9042), 1610-1614 (1996).
35. Marsh PJ, James RD, Schofeld PF. Adjuvant preoperative radiotherapy for locally advanced rectal carcinoma. Results of a prospective, randomized trial. Dis. Colon Rectum. 37(12), 1205-1214 (1994).
36. Thomas PR, Lindblad AS. Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience. Radiother. Oncol. 13(4), 245-252 (1988).
37. Fisher B, Wolmark N, Rockette H et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J. Natl Cancer Inst. 80(1), 21-29 (1988).
38. Heald RJ. A new approach to rectal cancer. Br. J. Hosp. Med. 22(3), 277-281 (1979).
39. Quirke P, Steele R, Monson J et al. Effect of the plane of surgery achieved on local recurrence in patients operated with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTGCO16 randomised clinical trial. Lancet 373(9666), 821-828 (2009).
40. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Sphincter preservation following preoperative radio-therapy for rectal cancer: Report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radio chemotherapy. Radiother. Oncol. 72(1), 15-24 (2004).
41. Ngan SY, Burmeister B, Fisher RJ et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. J. Clin. Oncol. 30(31), 3827-3833 (2012).
42. Marijnen CA, Kapiteijn E, van de Velde CJ et al. Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial. J. Clin. Oncol. 20(3), 817-825 (2002).
43. Loos M, Quentmeier P, Schuster T et al. Effect of preoperative radio(chemo)therapy on long-term functional outcome in rectal cancer patients: a systematic review and meta-analysis. Ann. Surg. Oncol. 20(6), 1816-1828 (2013).
44. Frykholm GJ, Glimelius B, Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: Final treatment results of a randomized trial and an evaluation of late secondary effects. Dis. Colon Rectum 36(6), 564-572 (1993).
45. Kendal WS, Nicholas G. A population-based analysis of second primary cancers after irradiation for rectal cancer. Am J. Clin. Oncol. 30(4), 333-339 (2007).
46. Lange MM, den Dulk M, Bossema ER et al. Risk factors for faecal incontinence after rectal cancer treatment. Br. J. Surg. 94(10), 1278-1284 (2007).
47. Pachler J, Wille-Jorgensen P. Quality of life after rectal resection for cancer, with or without permanent colostomy. Cochrane Database Syst. Rev. 12, CD004323 (2012).
48. Cornish JA, Tilney HS, Heriot AG, Lavery IC, Fazio VW, Tekkis PP. A meta-analysis of quality of life for abdominoperineal excision of rectum versus anterior resection for rectal cancer. Ann. Surg. Oncol. 14(7), 2056-2068 (2007).
49. Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 74(3), 673-688 (2009).
50. Koh D, Chau I, Tait D, Wotherspoon A, Cunningham D, Brown G. Evaluating mesorectal lymph nodes in rectal cancer before and after neoadjuvant chemoradiation using thin-section T2-weighted magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys. 71(2), 456-461 (2008).
51. Patel UB, Brown G, Rutten H et al. Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer. Ann. Surg. Oncol. 19(9), 2842-2852 (2012).
52. Patel UB, Taylor F, Blomqvist L et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J. Clin. Oncol. 29(28), 3753-3760 (2011).
53. Hunter CJ, Garant A, Vuong T et al. Adverse features on rectal MRI identify a high-risk group that may beneft from more intensive preoperative staging and treatment. Ann. Surg. Oncol. 19(4), 1199-1205 (2012).
54. Taylor FG, Quirke P, Heald RJ et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J. Clin. Oncol. 32(1), 34-43 (2014).
55. Strassburg J, Ruppert R, Ptok H et al. MRI-based indications for neoadjuvant radiochemotherapy in rectal carcinoma: interim results of a prospective multicenter observational study. Ann. Surg. Oncol. 18(10), 2790-2799 (2011).
56. Glimelius B, Tiret E, Cervantes A, Arnold D. ESMO Guidelines Working Group. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24(Suppl. 6), vi81-vi8 (2013).
57. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Rectal Cancer Version 2.2014. www.NCCN.org
58. Engelen SME, Maas M, Lahaye MJ et al. Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge. Eur. J. Cancer. 49(10), 2311-2320 (2013).
59. Taylor FG, Quirke P, Heald RJ et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann. Surg. 253(4), 711-719 (2011).
60. Blomqvist L, Glimelius B. The 'good', the 'bad', and the 'ugly' rectal cancers. Acta Oncol. 47(1), 5-8 (2008).
61. Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370 (9604), 2020-2029 (2007).
62. Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fuoropyrimidine-based chemotherapy provide a beneft for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann. Oncol. 21(12), 1743-1750 (2010).
63. Glimelius B. Adjuvant chemotherapy in rectal cancer-an issue or a nonissue? Ann. Oncol. 21(9), 1739-1741 (2010).
64. Petersen SH, Harling H, Kirkeby LT, Wille-Jørgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst. Rev. 3, CD004078 (2012).
65. Breugom AJ, van den Broek CBM, van Gijn W et al. The value of adjuvant chemotherapy in rectal cancer patients after preoperative radiotherapy or chemoradiation followed by TME-surgery: The PROCTOR/SCRIPT study. Presented at: 2013 European Cancer Congress, Amsterdam, The Netherlands, 27 September-1 October 2013 (Abstract 1).
66. Bosset JF, Collette L, Calais G et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N. Engl. J. Med. 355(11), 1114-1123 (2006).
67. Fernandez-Martos C, Pericay C, Aparicio J et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defned, locally advanced rectal cancer: Grupo Cancer de Recto 3 study. J. Clin. Oncol. 28(5), 859-865 (2010).
68. Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging-a meta-analysis. Radiology 232(3), 773-783 (2004).
69. Muthusamy VR, Chang KJ. Optimal methods for staging rectal cancer. Clin. Cancer Res. 13(22 Pt 2), s6877-s6884 (2007).
70. Al-Sukhni E, Milot L, Fruitman M et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann. Surg. Oncol. 19(7), 2212-2223 (2012).
71. Chua YJ, Barbachano Y, Cunningham D et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defned poor-risk rectal cancer: a Phase 2 trial. Lancet Oncol. 11(3), 241-248 (2010).
72. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 369(11), 1023-1034 (2013).
73. Stintzing S, Jung A, Rossius L et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized Phase III study of FOLFIRI plus cetuximab or bevacizumab as frst-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. 2013 European Cancer Congress, Amsterdam, The Netherlands, 27 September-1 October 2013 (Abstract LBA17).
74. Falcone A, Cremolini C, Masi G et al. FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as frst-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): results of the Phase III TRIBE trial by GONO group. J. Clin. Oncol. 31(Suppl.) Abstract 3505 (2013).
75. Sclafani F, Gonzalez D, Cunningham D et al. RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial. Eur. J. Cancer. 50(8), 1430-1436 (2014).
76. Merkel S, Mansmann. U, Siassi M, Papadopoulos T, Hohenberger W, Hermanek P. The prognostic inhomogeneity in pT3 rectal carcinomas. Int. J. Colorectal Dis. 16 (5), 298-304 (2001).
77. Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J. Clin. Oncol. 26(2), 303-312 (2008).
78. Valentini V, van Stiphout RG, Lammering G et al. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J. Clin. Oncol. 29(23), 3163-3172 (2011).
79. Wibe A, Syse A, Andersen E, Tretli S, Myrvold HE, SØreide O. Norwegian Rectal Cancer Group. Oncological outcomes after total mesorectal excision for cure for cancer of the lower rectum: anterior vs. abdominoperineal resection. Dis. Colon Rectum. 47(1), 48-58 (2004).
80. Chand M, Bhangu A, Wotherspoon A et al. EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy. Ann. Oncol. 25(4), 858-863 (2014).
81. MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. BMJ 333(7572), 779 (2006).
82. MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology 243(1), 132-139 (2007).
83. Smith NJ, Barbachano Y, Norman AR et al. Prognostic signifcance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. Br. J. Surg. 95(2), 229-236 (2008).
84. Koh D, Chau I, Tait D, Wotherspoon A, Cunningham D, Brown G. Evaluating mesorectal lymph nodes in rectal cancer before and after neoadjuvant chemoradiation using thin-section T2-weighted magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys. 71(2), 456-461 (2008).
85. Yu SK, Tait D, Chau I, Brown G. MRI predictive factors for tumor response in rectal cancer following neoadjuvant chemoradiation therapy-implications for induction chemotherapy? Int. J. Radiat. Oncol. Biol. Phys. 87(3), 505-511 (2013).
86. Ishii Y, Hasegawa H, Endo T et al. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fuorouracil, and leucovorin in patients with locally advanced rectal cancer. Eur. J. Surg. Oncol. 36(11), 1061-1065 (2010).
87. Cercek A, Weiser MR, Goodman KA et al. Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation. J. Clin. Oncol. 28(Suppl.), Abstract 3649 (2010).
88. Fernandez-Martos C, Estevan R, Salud A et al. Neoadjuvant capecitabine, oxliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) patients defned by magnetic resonance (MR): GEMCAD 0801 trial. J. Clin. Oncol. 30(Suppl.) Abstract 3586 (2012).
89. Uehara K, Hiramatsu K, Maeda A et al. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Jpn J. Clin. Oncol. 43(10), 964-971 (2013).
90. Schrag D, Weiser MR, Goodman KA et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J. Clin. Oncol. 32(6), 32-518 (2014).
91. Neoadjuvant FOLFOX6 Chemotherapy With or Without Radiation in Rectal Cancer (FOWARC). http://clinicaltrials.gov
92. Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery. http://clinicaltrials.gov
93. Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery (BACCHUS). http://clinicaltrials.gov
94. Fleming FJ, Monson JR. The contemporary (over) treatment of rectal cancer: the goldilocks effect. Dis. Colon Rectum 57(3), 403-406 (2014).